| Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study AH Madrid, MG Bueno, JMG Rebollo, I Marín, G Peña, E Bernal, ... Circulation 106 (3), 331-336, 2002 | 1219 | 2002 |
| Carotid intima-media thickness progression as surrogate marker for cardiovascular risk: meta-analysis of 119 clinical trials involving 100 667 patients P Willeit, L Tschiderer, E Allara, K Reuber, L Seekircher, LU Gao, X Liao, ... Circulation 142 (7), 621-642, 2020 | 499 | 2020 |
| MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network GB Migliori, S Tiberi, A Zumla, E Petersen, JM Chakaya, C Wejse, ... International Journal of Infectious Diseases 92, S15-S25, 2020 | 304 | 2020 |
| Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report S Borisov, E Danila, A Maryandyshev, M Dalcolmo, S Miliauskas, L Kuksa, ... European Respiratory Journal 54 (6), 2019 | 228 | 2019 |
| GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 E Pairo-Castineira, K Rawlik, AD Bretherick, T Qi, Y Wu, I Nassiri, ... Nature 617 (7962), 764-768, 2023 | 210 | 2023 |
| Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study C Orkin, S Oka, P Philibert, C Brinson, A Bassa, D Gusev, O Degen, ... The lancet HIV 8 (4), e185-e196, 2021 | 206 | 2021 |
| Pulmonary long-term consequences of COVID-19 infections after hospital discharge JR Blanco, MJ Cobos-Ceballos, F Navarro, I Sanjoaquin, ... Clinical Microbiology and Infection 27 (6), 892-896, 2021 | 185 | 2021 |
| Dalbavancin in the treatment of different gram-positive infections: a real-life experience E Bouza, M Valerio, A Soriano, L Morata, EG Carus, ... International journal of antimicrobial agents 51 (4), 571-577, 2018 | 175 | 2018 |
| The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases … AH Madrid, J Peng, J Zamora, I Marín, E Bernal, C Escobar, ... Pacing and clinical electrophysiology 27 (10), 1405-1410, 2004 | 156 | 2004 |
| Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase … C Orkin, EB Morell, DHS Tan, H Katner, HJ Stellbrink, E Belonosova, ... The lancet HIV 8 (11), e668-e678, 2021 | 151 | 2021 |
| Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19) J Rodríguez-Baño, J Pachón, J Carratala, P Ryan, I Jarrín, M Yllescas, ... Clinical Microbiology and Infection 27 (2), 244-252, 2021 | 149 | 2021 |
| Impact of late presentation of HIV infection on short-, mid-and long-term mortality and causes of death in a multicenter national cohort: 2004–2013 P Sobrino-Vegas, S Moreno, R Rubio, P Viciana, JI Bernardino, ... Journal of Infection 72 (5), 587-596, 2016 | 126 | 2016 |
| Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers AH Madrid, IM Marín, C Escobar Cervantes, E Bernal Morell, ... Journal of the Renin-Angiotensin-Aldosterone System 5 (3), 114-120, 2004 | 125 | 2004 |
| Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort YM Pacheco, I Jarrín, I Rosado, AA Campins, J Berenguer, JA Iribarren, ... Antiviral research 117, 69-74, 2015 | 107 | 2015 |
| Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients M Masiá, S Padilla, E Bernal, MV Almenar, J Molina, I Hernández, ... Clinical Therapeutics 29 (7), 1448-1455, 2007 | 102 | 2007 |
| Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment E Bernal, JM Gómez, I Jarrín, A Cano, A Muñoz, A Alcaraz, A Imaz, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 78 (3), 329-337, 2018 | 94 | 2018 |
| Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine over 48 weeks M Murray, A Antela, A Mills, J Huang, H Jäger, E Bernal, J Lombaard, ... AIDS and Behavior 24 (12), 3533-3544, 2020 | 86 | 2020 |
| The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients M Masiá, E Bernal, S Padilla, ML Graells, I Jarrín, MV Almenar, J Molina, ... Atherosclerosis 195 (1), 167-171, 2007 | 81 | 2007 |
| High-density lipoprotein cholesterol in HIV-infected patients: evidence for an association with HIV-1 viral load, antiretroviral therapy status, and regimen composition E Bernal, M Masiá, S Padilla, F Gutiérrez AIDS patient care and STDs 22 (7), 569-575, 2008 | 80 | 2008 |
| Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study O Akkerman, A Aleksa, JW Alffenaar, NH Al-Marzouqi, M Arias-Guillén, ... International Journal of Infectious Diseases 83, 72-76, 2019 | 67 | 2019 |
